351342-08-0 Usage
Description
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaoxanonapentacontane-1,59-diol, also known as Eicosa(ethylene glycol), is a polymer of ethylene glycol subunits with two terminal hydroxyl groups. The hydroxyl groups can react to further derivatize the compound, and the hydrophilic PEG linker increases the water solubility of the compound in aqueous media. The water solubility properties of the PEG chain are enhanced with longer PEG chains.
Uses
Used in Biopharmaceuticals:
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaoxanonapentacontane-1,59-diol is used as a component in the synthesis of phospholipid detergent conjugates for in vitro and in vivo gene delivery and other biopharmaceuticals. The hydrophilic PEG linker enhances the water solubility of these conjugates, improving their bioavailability and therapeutic outcomes.
Used in Gene Delivery:
In the Gene Delivery industry, 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaoxanonapentacontane-1,59-diol is used as a key component in the development of phospholipid detergent conjugates. These conjugates facilitate the delivery of genetic material into cells, allowing for the potential treatment of various genetic disorders and diseases.
Used in Drug Delivery Systems:
3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaoxanonapentacontane-1,59-diol is utilized in the design of drug delivery systems to improve the solubility and bioavailability of various pharmaceutical compounds. The hydrophilic nature of the PEG chain aids in the dispersion of drugs in aqueous environments, enhancing their overall effectiveness.
Used in Cosmetics and Personal Care:
In the Cosmetics and Personal Care industry, 3,6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57-nonadecaoxanonapentacontane-1,59-diol is used as an ingredient in various formulations due to its water solubility and hydrophilic properties. It can improve the texture, consistency, and skin feel of products, making it a valuable component in the development of creams, lotions, and other personal care products.
Check Digit Verification of cas no
The CAS Registry Mumber 351342-08-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,1,3,4 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 351342-08:
(8*3)+(7*5)+(6*1)+(5*3)+(4*4)+(3*2)+(2*0)+(1*8)=110
110 % 10 = 0
So 351342-08-0 is a valid CAS Registry Number.
351342-08-0Relevant articles and documents
Highly efficient synthesis of monodisperse poly(ethylene glycols) and derivatives through macrocyclization of oligo(ethylene glycols)
Zhang, Hua,Li, Xuefei,Shi, Qiuyan,Li, Yu,Xia, Guiquan,Chen, Long,Yang, Zhigang,Jiang, Zhong-Xing
, p. 3763 - 3767 (2015/03/18)
A macrocyclic sulfate (MCS)-based approach to monodisperse poly(ethylene glycols) (M-PEGs) and their monofunctionalized derivatives has been developed. Macrocyclization of oligo(ethylene glycols) (OEGs) provides MCS (up to a 62-membered macrocycle) as versatile precursors for a range of monofunctionalized M-PEGs. Through iterative nucleophilic ring-opening reactions of MCS without performing group protection and activation, a series of M-PEGs, including the unprecedented 64-mer (2850Da), can be readily prepared. Synthetic simplicity coupled with versatility of this new strategy may pave the way for broader applications of M-PEGs. Macrocycles make synthesis easier: Convenient macrocyclization of the OEGs provides versatile macrocyclic sulfates. These compounds are cornerstones for both monofunctionalization of OEGs and highly efficient synthesis of monodisperse PEGs and derivatives, including an unprecedented 64-mer.
Fluorous synthesis of mono-dispersed poly(ethylene glycols)
Li, Yu,Guo, Qi,Li, Xuefei,Zhang, Hua,Yu, Fanghua,Yu, Weijiang,Xia, Guiquan,Fu, Mingyang,Yang, Zhigang,Jiang, Zhong-Xing
supporting information, p. 2110 - 2113 (2014/04/03)
Mono-dispersed poly(ethylene glycols) (PEGs) are of great value in the development of biopharmaceuticals. However, tedious synthesis limits the availability of mono-dispersed PEGs. To address this issue, a fluorous synthesis of mono-dispersed PEGs, discretely PEGylated surfactants and 19F magnetic resonance imaging (MRI) agents has been developed. During the synthesis, both fluorous and normal phase silica gel-based solid-phase extractions were successfully employed to simplify the purifications. This synthesis provided an easy access to valuable mono-dispersed PEGs and related molecules for biomedical application on multi-gram scales.
